BioSpace News Archive

Cytovale® announced that the first hospital to commercially implement the company’s IntelliSep® rapid sepsis diagnostic has now screened over 5,000 patients with the test.

Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously undruggable disease targets

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, and Alphazyme LLC, a Maravai LifeSciences company and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies’ previously announced Linea™ RNAP manufacturing scale-up agreement.

MCRA, the leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm is pleased to announce its role in the U.S. Food and Drug Administration’s (FDA) De Novo granting for Onkos Surgical’s antibacterial coating for tumor and revision orthopedic implants.

The global biomarkers market was evaluated at US$ 82.30 billion in 2023 and is expected to attain around US$ 318.76 billion by 2033, growing at a CAGR of 14.5% from 2024 to 2033.

Gemina Laboratories Ltd. is pleased to announce that it has qualified for trading on the OTCQB Venture Market in the United States operated by the OTC Markets Group Inc. and the Company’s common shares have commenced trading on the OTCQB under the symbol “GLABF.” The Company’s common shares will continue to trade on the CSE Exchange under the symbol “GLAB” and on the Frankfurt Exchange under the symbol “817".

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing.

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced the completion of its previously announced merger with AVROBIO, Inc.

Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical stage pharmaceutical company, today announced that management will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.